Immunotherapy: Open Access
Open Access

Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Publications

• Research Article   
  The Synergistic Antitumor Efficacy of Lienal Polypeptide Combined with EGFR-TKIs for Advanced NSCLC
  Author(s): Yun Chen, Xinyin Liu, Jiaqi Yao, Shidai Jin, Jun Li, Jiali Xu and Renhua Guo*
  
  Purpose: EGFR-TKIs are the first-line therapy for advanced NSCLC harboring EGFR-sensitive mutations. A robust immunity is an essential foundation for patients to tolerate continuous drug treatments. Lienal Polypeptide (LP) is an immunomodulator widely applied to regulate immunity in clinical practice. Nevertheless, its potential impact on EGFR-TKIs therapy has not been illustrated. This study aimed to explore the immunomodulatory and antitumor efficacy of LP in combination with EGFR-TKIs threapy in advanced NSCLC. Patients and methods: Retrospective analysis on variation of lymphocytes in 106 NSCLC patients after EGFR-TKIs combined with LP treatment was performed. Proliferation experiment, transwell and wound healing assays were performed in PC9-GR cells to estimate influence of LP on tumor proliferation, invasion and migration in vitro.. View More»
  DOI: 10.35248/2471-9552.22.8.197

  Abstract HTML PDF